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Abstract
A discussion about disadvantages of electronic cigarettes (e-cigarettes) has recently broken out. There are even opinions that 
they are as harmful as regular cigarettes. However, this has not been proved, and theoretical premises suggest that e-cigarettes 
should be definitely less harmful as while using them, tobacco is not burned and harmful substances, in particular carcinogens 
are not produced. Certain premises assume that e-cigarettes may be used as a new form of nicotine replacement therapy, but 
this has not been confirmed yet. Therefore, further research into harmfulness and safety of the use of e-cigarettes is required. This 
paper presents solely reasons for the possibility of recommending e-cigarettes to people addicted to nicotine.
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Introduction
A discussion about electronic cigarettes (the 
so-called e-cigarettes) has been held for some time 
now. A special issue of Tobacco Control (2014 
Suppl 2) has been devoted to the problem. Calla-
han-Lyon concluded in one of the study [1] that 
scientific evidence concerning impact of e-ciga-
rettes on human health is limited, and although 
their aerosol includes less harmful substances 
compared to regular cigarettes, researches eval-
uating their influence on health are inconclusive 
and the American Food and Drug Administration 
(FDA) does not allow them to be used as treatment 
for nicotine dependence due to lack of sufficient 
evidence. The impact of the passive use of e-cig-
arettes on health of people from the environment 
of e-cigarettes users is unknown either. More and 
more researches focus on the issue but there are no 
long-term randomized double-blinded multicentre 
studies assessing large populations that would 
provide respectively strong and reliable arguments 
for and against the use of e-cigarettes. At present 
we have solely experts’ opinions that are not con-
firmed with evidence that would enable unanimous 
recommendations. These doubts will be certainly 
soon resolved. This paper presents only suggestions 
concerning the possibility of recommending e-cig-
arettes to individuals addicted to nicotine.
Composition of tobacco smoke and e-cigarette 
aerosol
To begin with, we compare cigarette smoke 
with e-cigarette aerosol. A cigarette is a tobacco 
product, in which tobacco leaves are wrapped 
in thin tissue paper. While smoking a cigarette, 
tobacco is burned and the smoker is inhaling 
smoke including approximately 4 thousand of 
chemical substances such as benzopyrene, tarry 
substances, carbon monoxide, acetone, butane, 
vinyl chloride, ammonia, arsenic, toluidine, form-
aldehyde, phenols, hydrocyanic, naphthylamine, 
carbinol, 2-benzoacridine, dichlorodiphenylotri-
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chloroethane, dimethylonitrosamine, cadmium, 
polonium, urethane [2].
E-cigarette is a device that enables the user 
to inhale nicotine. The main difference lies in 
the lack of tobacco combustion that produces so 
many harmful to health substances. Liquid used 
in e-cigarettes contains propylene glycol, glycer-
ine, nicotine and flavourings [3]. It is heated up to 
the temperature allowing transition from liquid to 
gazeous phase, which then is inhaled to the lungs. 
Trace amounts of toxic substances were found 
in e-cigarette vapours but the levels of toxicants 
were 9-450 times lower than in cigarette smoke 
and did not exceed the levels authorised for use 
[4]. They came from contaminated tobacco, which 
was used in the production of nicotine and then 
utilised in e-cigarette.
Cigarette smoke and e-cigarette aerosol  
— harmfulness to health
Recent decades have provided powerful ev-
idence for the harmfulness of nicotine smoking 
[5, 6]. There is no doubt that the addiction is the 
cause of many fatal diseases, it shortens life of 
million of people, causes inability to work and 
generates huge direct and indirect costs. Tobac-
co became a big killer in the 20th century and 
it brought death to more people than any war. 
Popularity of tobacco smoking lead to a dramatic 
increase in prevalence of cancer. At least 40 com-
ponents of tobacco smoke (e.g. tarry substances, 
cadmium, benzopyrene, vinyl chloride, 2-ben-
zoacridine, toluidine, naphthylamine) impact on 
development of malignant cancer [7]. It has been 
proved that nicotine smoking affects development 
of leukaemia and cancer in various organs such 
as the lungs, larynx, throat, oesophagus, stomach, 
kidney, urinary bladder, pancreas, liver, nose, 
uterine cervix [8]. Due to popularity of tobacco 
smoking, lung cancer is the most frequent ma-
lignant cancer causing 30% of all cases of deaths 
because of this condition [9]. Harmful influence 
of tobacco smoking on health is not limited to 
carcinogenic effects. It also causes diseases of 
the respiratory tract such as chronic bronchitis, 
chronic obstructive pulmonary disease (COPD), 
emphysema, bronchial asthma etc. [10]. Cigarette 
smoke has also an effect on diseases of the car-
diovascular system, in particular atherosclerosis, 
arterial hypertension, ischaemic heart disease, 
myocardial infarction, aortic aneurysm and 
diseases of the nervous system such as cerebral 
stroke, cerebral thrombosis and subarachnoid 
haemorrhage [11, 12]. Each year over 4 million 
people die due to tobacco smoking [13]. Cigarette 
smoking leads to greater vulnerability to bacterial 
and viral infections, including tuberculosis [14, 
15]. It has been also shown that tobacco smok-
ing impacts negatively on the development of 
diseases of the alimentary tract such as chronic 
gastric and duodenal ulcer disease, gastroesopha-
geal reflux, Lesniowski-Crohn disease, ulcerating 
inflammation of the large intestine, intestinal 
hernia [16, 17]. Furthermore, tobacco smoking 
has been found to influence the development of 
osteoporosis, parodontopathy, cataract, macular 
degeneration, early skin aging [18–20]. Cigarette 
smoking has a negative effect on the reproductive 
system, resulting in small birth weight of the new-
born, premature detachment of the placenta or 
rupture of the membranes, difficulty in becoming 
pregnant and early menopause [21, 22].
When the disadvantages of nicotine smoke 
are recalled, e-cigarettes seem to be much safer 
to health. They include merely several mentio-
ned substances with nicotine having the most 
significant harmful effect on health. Nicotine 
adversely impacts on the cardiovascular system 
as it causes shrinkage of the walls of the blood 
vessels (including also the coronary vessels), in-
creases blood pressure, accelerates the frequency 
of heart beating, leads to heart rhythm disorders 
and rises the risk of thrombosis [23]. It is also a 
powerful neurotoxin. Additionally, it indirectly 
affects the growth of neoplasms because it ne-
gatively influences the p53 gene, which hinders 
uncontrollable development of neoplastic cells 
[24]. Therefore, harmful effect of nicotine smoke 
on health is incomparably greater than that of 
e-cigarette aerosol. Electronic cigarette aerosol 
induces significantly less cytotoxicity than tobac-
co smoke [25]. Although many flavourings used 
in e-cigarettes are generally recognised as safe 
when used in food products, concerns have been 
raised about the potential inhalation toxicity of 
these chemicals [26]. Benzaldehyde, which is a 
key ingredient in natural fruit flavours, has been 
shown to cause irritation of respiratory airways 
in animal and occupational exposure studies [26].
The lesser of two evils principle
Analysis of the causes of unsuccessful ces-
sation of tobacco smoking was the basis for 
invention of a device delivering nicotine via in-
halation - the so-called e-cigarette. Many people 
who smoke cigarettes are nicotine dependent, 
which is only one of many harmful components 
of cigarette smoke. Thus, in accordance with the 
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lesser of two evils principle, the idea of the use of 
nicotine, which is the cause of addiction, without 
other toxic, in particular carcinogenic chemical 
substances was generated. The Polish Consensus 
on the Diagnostics and Treatment of Tobacco De-
pendence includes a statement that although, in 
the opinion of both smokers and doctors, the use 
of nicotine is controversial, harmfulness of small 
doses of pure nicotine is slight and incomparable 
to effects exerted by thousands of chemical sub-
stances included in tobacco smoke [27]. It was 
stated that even pregnancy and past myocardial 
infarction should not be treated as contraindica-
tion for nicotine replacement therapy [27].
Such a standpoint puts doctors in a position 
that does not allow them to oppose the use of 
e-cigarette as they may be suspected of being 
inconsistent, recommending delivery of nicotine 
via chewing gum, nicotine patches, tablets or 
inhalers, and simultaneously disapproving of 
delivery of nicotine with the help of e-cigarette. 
The opponents of e-cigarettes discuss the problem 
of uncontrollable use of high doses of nicotine, 
but such risk is also involved in other forms of 
nicotine replacement therapy, as they may be 
purchased without prescription and high price 
may be the only obstacle to acquire them.
The possibility of the use of e-cigarette  
in treatment of nicotine dependence
There are premises that e-cigarettes may be 
used in nicotine replacement therapy. They have 
been the most popular, best investigated and used 
for 25 years now method of pharmacological tre-
atment of tobacco dependence [27]. It replaces 
nicotine included in tobacco smoke with “pure 
nicotine” in order to appease the lack of nicotine 
at the moment of smoking cessation [27]. Marke-
ting information underlines that e-cigarettes help 
to quit smoking or reduce the number of cigarettes 
used. However, this has been confirmed by few 
researches [28–30]. They showed that the use of 
e-cigarettes allowed to reduce the number of re-
gular cigarettes. Such survey was also conducted 
in Poland [31]. It included approximately 200 
people, of whom 66% stopped smoking, and 25% 
smoked less than 5 cigarettes a day [31]. How-
ever, the obtained data are not reliable enough to 
allow FDA to recommend e-cigarette for nicotine 
replacement therapy. In randomized controlled 
trials and multiple cohort studies, still differential 
association between e-cigarette use and cessation 
rates was seen [32].
Reduction of negative effects of passive  
tobacco smoking
Cigarette smoking is dangerous not only 
for smokers alone but also for people from their 
environment (the so-called passive smokers) 
[33, 34]. The contents of e-cigarette aerosol re-
leased to the environment during exhalation is 
changeable and depends on the technique used 
and other factors such as air temperature [35]. 
Nicotine from aerosol may remain on various 
surfaces for many weeks or even months [35]. 
It is difficult to clearly assess the impact on 
individuals not using e-cigarettes but to date 
no evidence for their harmfulness in passive 
smokers was provided. The absolute impact 
from passive exposure to e-cigarettes vapour has 
the potential to lead to adverse health effects, 
however the risk is likely to be less than the risk 
from passive exposure to conventional cigarette 
smoke [36].
E-cigarettes and children
The issue of the use of e-cigarettes by children 
and adolescents is under discussion [37, 38]. Data 
about harmful effect of e-cigarettes on children 
are limited. Available facts show rapid growth in 
the use of e-cigarettes by adolescents [38]. Howe-
ver, the thesis that nicotine dependence in youth 
results in tobacco use in the future has not been 
proved. Restricting the range of e-cigarette flavors 
(e.g., eliminating sweet flavors, like fruit and can-
dy) may benefit youth and young adult prevention 
efforts [39].
Evidenced harmfulness of e-cigarettes
The use of e-cigarettes causes irritation of 
the mucosa of the throat and oral cavity, and dry 
cough — but these symptoms are reduced with 
time [1]. Raised inflammatory markers [1] or 
changes in blood morphology [40] were not ob-
served. The use of e-cigarette did not impact on 
spirometry of the lungs but these findings come 
from observations of short duration [41]. Other 
results concern reduced amounts of nitrogen 
oxide in exhaled air and increase in respiratory 
impedance and resistance in the bronchial tree 
similar to the effects after the use of regular 
cigarettes [42]. Whereas on echocardiography, 
no changes in the heart functions [43] or signi-
ficant changes in the number of heartbeats were 
observed [44].
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For and against the use of e-cigarette
It has to be admitted that most arguments 
against tobacco smoking cannot be applied in 
the case of e-cigarettes. There are no data sho-
wing increased prevalence of serious diseases 
or health consequences in people using them. 
No sensation of fatigue, lack of sleep or worse 
physical condition due to worse oxygenation of 
the organism were noted. The use of e-cigarettes 
does not lead to yellow teeth, bad breath, poor 
condition of skin, hair and nails, development of 
lipodystrophy or rapid skin aging. They do not 
leave unpleasant smell on clothes, home, hands 
or mouth, which is so important for women when 
they consider smoking cessation. Contrary to 
cigarettes, increased risk of osteoporosis, earlier 
menopause or difficulties in becoming pregnant 
were not shown. In men, tobacco smoking redu-
ces sexual function and fertility, which was not 
observed after the use of e-cigarette. Cough and 
hoarseness are considerably less intensive, com-
pared to cigarette smoking. For in the majority 
of countries there are no regulations limiting the 
use of e-cigarettes, their use is not associated 
with uncomfortable ban on smoking at work or 
in public places, or anxiety over lack of cigarettes 
or impossibility of smoking. The use of e-cigarette 
does not provoke conflict between nonsmoking 
persons, it does not bring remorse caused by po-
isoning other people or a such evident negative 
example for children.
But the problems related to nicotine depen-
dence such as compulsion to smoke, limited free-
dom, the feeling of being a mentally weak person 
still remain. Cigarette smoking is also connected 
with loss of time. In the case of a person smo-
king one packet of cigarettes a day it equals 100 
minutes per day. Although e-cigarettes are less 
expensive than traditional cigarettes, the use of 
them is associated with unnecessary expenses.
Time will verify doubts connected with the 
use of e-cigarettes. The results of the conducted 
researches will show the harmfulness of the use 
of e-cigarettes to the users and people from their 
environment, and to what extent they may be 
used in treatment of nicotine dependence. It is 
worth remembering that the name of nicotine 
originates from the name of a French doctor who 
recommended tobacco as medication.
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